IGMS
IGM Biosciences, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website igmbio.com
- Employees(FY) 290
- ISIN US4495851085
Performance
-12.05%
1W
-27.17%
1M
-7.59%
3M
+15.45%
6M
+14.2%
YTD
+53.06%
1Y
Profile
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Technical Analysis of IGMS 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-06 08:16
- 2024-11-10 07:06
- 2024-11-08 08:00
- 2024-11-08 07:00
- 2024-11-07 18:00
- 2024-11-07 06:34
- 2024-11-04 07:00
- 2024-11-03 18:00
- 2024-10-18 07:36
- 2024-10-01 17:09
- 2024-10-01 16:03
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover(Investor's Business Daily)
- 2024-10-01 12:33
- 2024-10-01 11:40
- 2024-10-01 09:12
- 2024-10-01 08:00
- 2024-10-01 07:40
Top Premarket Decliners(MT Newswires)
- 2024-10-01 07:27
- 2024-10-01 07:20
- 2024-10-01 07:14
- 2024-10-01 07:03
- 2024-10-01 06:34
- 2024-09-30 20:00
- 2024-09-30 17:06
- 2024-09-30 16:01
- 2024-09-30 04:01
- 2024-09-27 06:54
- 2024-09-18 09:33
- 2024-09-10 16:05
- 2024-09-10 04:05
- 2024-08-22 09:04
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.